Project Grant R34AR084718

Award Date 7/15/24
Completion Date 12/31/25
Dollars Obligated $247K
Federal Grant Program
93.846
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21201, USA
Similar Awards
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $1,037,340 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to The Broad Institute, Inc. The grant will be used to transform the Musculoskeletal Knowledge Portal (MSKKP) into an established biomedical knowledgebase. The project aims to integrate numerous genomic datasets in bone, cartilage, tendon, synovial fluid, and muscle from international...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $456,808 to the Buck Institute for Research on Aging to develop innovative mass spectrometry imaging (MSI) technologies and advanced proteomic profiling approaches. The goal is to spatially visualize proteins and glycans in musculoskeletal tissues, particularly bone and cartilage, to better...
This Project Grant award, worth $375,100.00, was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award, effective from September 20, 2024 to August 31, 2026, will support research to identify myeloid progenitors that aid in maintaining cortical bone mass with age and characterize cells/molecules that promote bone remodeling in the cortical bone compartment. The...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $220,224 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to The Regents of the University of Colorado. The award, titled "GRANULAR HYDROGELS FOR THE CONTROLLED DELIVERY OF IMMUNOMODULATORY AND ANGIOGENIC EXTRACELLULAR VESICLES TO ENHANCE BONE TISSUE REGENERATION," began on July 4, 2024 and is scheduled for completion by August 31, 2027. The...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $388,960 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to the Medstar Health Research Institute Inc. to evaluate the use of machine learning algorithms to analyze accelerometry data and track functional upper extremity use in patients recovering from distal radius fractures. The project aims to develop a suite of algorithms that can accurately differentiate functional...
This federal Project Grant award of $644,887 was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award will support research conducted by the University of Rochester to investigate the role of the WNT16 protein in hip osteoarthritis progression, with a focus on understanding the genetic and epigenetic mechanisms by which mechanical loading regulates WNT16...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $468,769 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to The Washington University to conduct preclinical research evaluating physical and biological interventions to reduce post-traumatic joint contracture (PTJC). The 5-year project aims to identify key parameters of physical therapy protocols and anti-inflammatory/immune system modulation strategies that can best...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will provide $483,070 to the University of Missouri at Kansas City (UMKC) to conduct research on the dynamics of bone extracellular matrix (ECM) assembly and resorption. The key objectives are to understand how osteogenic cellular dynamics, differentiation, and fate are integrated with collagen...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $1,744,358 to the University of Maryland, Baltimore to develop novel analytical methods for analyzing post-fracture recovery trajectories in older adults with Alzheimer's disease and related dementias (ADRD). The project aims to: 1) Identify patient characteristics associated with poor longitudinal recovery outcomes, 2) Develop joint modeling approaches to uncover shared mechanisms and enable...
This Project Grant award for $578,944.00, provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports research to decipher the genetics of osteoarthritis (OA) susceptibility, heterogeneity, and progression. The key objectives are to: 1) identify new and fine-map known genetic loci associated with susceptibility to OA and total hip/total knee arthroplasty; 2)...

This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will support the development of a Musculoskeletal Adaptive Platform Trial (MAPT). The $246,800 award, effective July 15, 2024 through December 31, 2025, will enable the University of Maryland, Baltimore to complete planning and infrastructure establishment for this highly efficient adaptive clinical trial platform. The key objectives are to: 1) perform computer simulations to determine adaptation parameters, 2) establish stakeholder groups and decision-making structures, and 3) set up the necessary clinical trial infrastructure. This planning effort aims to position the MAPT platform to efficiently compare multiple interventions for improving outcomes in the population of older adults with lower extremity, pelvic, or acetabular fractures, a group that currently experiences unacceptably poor outcomes despite advances in clinical research.

Generated 6/10/25, 5:55 AM